Depression News: Exciting Breakthroughs in Treatment for Major Depressive Disorder

Updated on January 15, 2020

Food and Drug Administration (FDA) has endorsed the designation Breakthrough Therapy to AXS-05. As announced, the drug product will treat the major depressive disorder (MDD).

For half a century, the science behind antidepressants has not advanced. But, do you know depression patients have new hope? Discoveries in depression news will change everything. This includes anesthetic ketamine.

What’s The Hope in Depression News?

According to research published by Chronisseur, depression and anxiety can greatly be reduced with light therapy, fish oil and regular exercise.

Major depressive disorder (MDD) leads to causing disability in the world. Mood disorder affects about 300 million people globally. Unfortunately, the traditional treatments discovered in the 1960s and 70s failed many patients.

One out of three patients didn’t receive medication benefits. Meanwhile, one out of five MDD patients suffers from treatment-resistant depression. Check this guide to learn about the newest breakthroughs in depression treatment.

Esketamine Breakthrough

The U.S. FDA granted esketamine breakthrough therapy to handle treatment-resistant depression. The body will weigh the esketamine nasal spray. What happens if it gets the FDA approval?

 It will be the foremost non-monoamine drug to treat depression. Since discovery in the 1950, it will be the first antidepressant mechanism. Through the science of depression, the lives of many patients will change.

Depression research will bring change for the millions who didn’t find hope. Not everyone benefited from selective serotonin reuptake inhibitors.

What Do Depression Researchers Say?

There is interconnecting of stress, neurogenesis and depression. Neurogenesis likely occurs in major areas of adults, for instance, the hippocampus. Stress hormones like CRF disrupt neurogenesis.

This is what they do: they close the Brain-Derived Neurotrophic Factor (BDNF). BDNF deals in the production of new neurons, their survival, and even growth. Neurogenesis and producing of BDNF shut down with stress.

It helps to elaborate the reduced hippocampal volume during the depression. Antidepressants also reverse alterations in BDNF and brain structure.

The science of depression is at a promising phase despite the misconception. Did you know biological triggers are causes of major depression? Yes, they do.

Biologic Predisposition to Depression

There is compelling evidence on biologic predisposition to depression. The disorder is likely familial and predisposed.

The data come from twin studies, family studies, genetic findings, and adoption studies.

What about the early recurrent types of depression? Research indicates that added risk to initial degree relatives will remain higher. That’s compared to relatives of nondepressed probands.

Early-onset adverse upshots include nausea, anxiety, insomnia, agitation, and somnolence. Sleep disturbances are often persistent, but the early-onset adverse impacts are transient.

That’s why there is the importance of permitting adaptation. Besides, it’s significant to address patient compliance. It should be from the starting of acute treatment to achieve and maintain response.

Why End Anxiety?

It should be a priority to drop anxiety early during treatment. Waiting for adaption is an option. Pharmacologic antidotes or decrease of the dose comes in handy. To end nausea you can:

  • Lower the dose
  • Use antagonists
  • Apply 5HT3 (serotonin receptor subtype)

You can enhance somnolence with altered dosing or with nighttime. What about in extreme circumstances? A stimulant augmentation or medication switch can be efficacious.

Impacts of late-onset adverse include weight gain, asthenia, discontinuation syndrome, and sexual dysfunction.

Major Points Highlighted

  • Matching patient needs with antidepressant profiles can enhance compliance.
  • Initial drug selection has this primary goal: adaptation or full therapeutic response.
  • The newer antidepressants can cut adverse events and optimize efficacy.
  • Effects of early-onset side effects are usually transient.
  • Drug selection should reduce late-onset side effects and persistent.
  • You change interventional strategies over the treatment course. That’s based on initial treatment and individual patient needs.

Attention of the Clinician

For adverse events, there should be immediate attention by a clinician. The emerging of an adverse occurrence isn’t attributed immediately to a new treatment.

It’s good to consider the following plausible options: psychiatric illness / comorbid medical illness

  • Discontinuation syndrome
  • Medication interaction
  • Depression symptom

Depression researchers should advance their studies on the human genome. It should also emphasize on the heuristic efforts nature. That’s done by comprehending antidepressant action mechanisms.

Focuses on Ezogabine

There is an avenue focus on ezogabine; an anticonvulsant drug. FDA approved the potassium ion icebreaker to treat partial seizures.

The aim is to view any protective effect for those facing extreme stress. In animal research, infused or injected ezogabine delivered minimized depression symptoms.

The symptoms included reduced motivation, loss of interest, and inability to feel pleasure. There is the potential of ezogabine to normalize neuron hyperactivity. That’s in supplementing the active resilience mechanisms in mind.

Common Prescribed Antidepressants

Selective serotonin reuptake inhibitors are the most usually prescribed antidepressants. Those may include Zoloft and Prozac.

They block neurons from reabsorbing neurotransmitter serotonin. That makes the chemical to accumulate more in the brain.

After several weeks or months, the process eases depression in some patients. Resistant to the treatment in MDD patients brings the glutamate system closer.

Depression and chronic stress seem to alter the synapses and glutamate receptors. That causes loss of synaptic structure.

Effect of Ketamine on NMDA

Ketamine has a great affinity for the NMDA (N-methyl-d-aspartate) receptor. NMDA is among the primary glutamate brain receptors.

The drug prevents the NMDA from re-uptaking the secreted glutamate. By restoring the normal levels of glutamate, ketamine revives connections between neurons. Besides, it restores brain neuroplasticity within a day.

New Ways to Treat MDD

Depression researchers are pursuing various ways that can lead to MDD treatment. The interleukin-6 molecule is among the investigative targets. The protein has the following roles:

  • Mediates inter-cells communication
  • Stimulates inflammation in depression suffering patients

According to depression research, check it out patients have unusual levels of IL-6. The finding has enhanced research of other factors that affect inflammatory pathways. The study includes its capability to help neuro-circuits in controlling depression.

Wrap Up

The science of depression is still giving hope to millions of affected people. As you can see, the available antidepressants show comparable efficacy during acute phases.

Some of the newer antidepressants give early relief to sleep disturbance and anxiety.

What are depression indicators and likely antidepressant side effects? We want you equipped with the latest news and relevant information.

Bookmark our page or make contact with us for more highlights and depression news.

+ posts

Throughout the year, our writers feature fresh, in-depth, and relevant information for our audience of 40,000+ healthcare leaders and professionals. As a healthcare business publication, we cover and cherish our relationship with the entire health care industry including administrators, nurses, physicians, physical therapists, pharmacists, and more. We cover a broad spectrum from hospitals to medical offices to outpatient services to eye surgery centers to university settings. We focus on rehabilitation, nursing homes, home care, hospice as well as men’s health, women’s heath, and pediatrics.